Key facts
- Moonlight Therapeutics’s last known valuation is $7.9M (Aug 2024).
- It has raised $2.4M across 1 recorded rounds; the latest was Seed Round ($2.4M) in Aug 2024.
- Notable investors include SOSV, National Institutes of Health, IndieBio, Advanced Technology Development Center, AllerFund Ventures — 10 tracked in total.
- Moonlight Therapeutics has filed 1 Form D with the SEC, most recently Aug 2024 ($2.4M sold to 30 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Moonlight Therapeutics
Funding rounds
1 roundsAbout Moonlight Therapeutics
Developer of intradermal therapy designed to transform the lives of people with food allergies. The company offers a small, painless intradermal stamp providing at-home administration with effective desensitization, enabling individuals with peanut allergies to reduce their risk of dangerous allergic reactions and support safer daily living.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2017
- Employees
- 6
- Website
- moonlighttx.com/
- Ownership
- Privately Held (backing)
Moonlight Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Moonlight Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Moonlight Therapeutics in its N-PORT filings yet. We sweep new filings monthly.